GSK2838232
|
G648771-5mg
|
≥99% |
1443460-91-0 |
5mg
|
¥ 1700.9
|
期货,请咨询 |
阿拉丁 |
GSK2838232
|
G648771-50mg
|
≥99% |
1443460-91-0 |
50mg
|
¥ 9500.9
|
期货,请咨询 |
阿拉丁 |
GSK2838232
|
G648771-25mg
|
≥99% |
1443460-91-0 |
25mg
|
¥ 5900.9
|
期货,请咨询 |
阿拉丁 |
GSK2838232
|
G648771-1mg
|
≥99% |
1443460-91-0 |
1mg
|
¥ 647.9
|
期货,请咨询 |
阿拉丁 |
GSK2838232
|
G648771-10mg
|
≥99% |
1443460-91-0 |
10mg
|
¥ 2700.9
|
期货,请咨询 |
阿拉丁 |
GSK2838232
|
G648771-100mg
|
≥99% |
1443460-91-0 |
100mg
|
¥ 15000.9
|
期货,请咨询 |
阿拉丁 |
GNE-900
|
G648750-5mg
|
|
1200126-26-6 |
5mg
|
¥ 2000.9
|
期货,请咨询 |
阿拉丁 |
GNE-900
|
G648750-50mg
|
|
1200126-26-6 |
50mg
|
¥ 13000.9
|
期货,请咨询 |
阿拉丁 |
GNE-900
|
G648750-25mg
|
|
1200126-26-6 |
25mg
|
¥ 7400.9
|
期货,请咨询 |
阿拉丁 |
GNE-900
|
G648750-10mg
|
|
1200126-26-6 |
10mg
|
¥ 3500.9
|
期货,请咨询 |
阿拉丁 |
GLP-1 receptor agonist 2
|
G648746-5mg
|
≥98% |
2230197-64-3 |
5mg
|
¥ 4500.9
|
期货,请咨询 |
阿拉丁 |
GLP-1 receptor agonist 2
|
G648746-50mg
|
≥98% |
2230197-64-3 |
50mg
|
¥ 21000.9
|
期货,请咨询 |
阿拉丁 |
GLP-1 receptor agonist 2
|
G648746-25mg
|
≥98% |
2230197-64-3 |
25mg
|
¥ 15000.9
|
期货,请咨询 |
阿拉丁 |
GLP-1 receptor agonist 2
|
G648746-10mg
|
≥98% |
2230197-64-3 |
10mg
|
¥ 7500.9
|
期货,请咨询 |
阿拉丁 |
GLP-1 receptor agonist 2
|
G648746-100mg
|
≥98% |
2230197-64-3 |
100mg
|
¥ 33000.9
|
期货,请咨询 |
阿拉丁 |
Goflikicept
|
G648742-5mg
|
|
2416984-26-2 |
5mg
|
¥ 15000.9
|
期货,请咨询 |
阿拉丁 |
Goflikicept
|
G648742-1mg
|
|
2416984-26-2 |
1mg
|
¥ 6000.9
|
期货,请咨询 |
阿拉丁 |
GSK215
|
G648707-5mg
|
≥99% |
2743427-26-9 |
5mg
|
¥ 3072.9
|
期货,请咨询 |
阿拉丁 |
GSK215
|
G648707-50mg
|
≥99% |
2743427-26-9 |
50mg
|
¥ 15000.9
|
期货,请咨询 |
阿拉丁 |
GSK215
|
G648707-25mg
|
≥99% |
2743427-26-9 |
25mg
|
¥ 9280.9
|
期货,请咨询 |
阿拉丁 |
GSK215
|
G648707-10mg
|
≥99% |
2743427-26-9 |
10mg
|
¥ 4920.9
|
期货,请咨询 |
阿拉丁 |
GSK215
|
G648707-100mg
|
≥99% |
2743427-26-9 |
100mg
|
¥ 24000.9
|
期货,请咨询 |
阿拉丁 |
Guanosine 5'-triphosphate trisodium salt hydrate
|
G648693-50mg
|
|
207300-85-4 |
50mg
|
¥ 520.9
|
期货,请咨询 |
阿拉丁 |
Guanosine 5'-triphosphate trisodium salt hydrate
|
G648693-500mg
|
|
207300-85-4 |
500mg
|
¥ 2280.9
|
期货,请咨询 |
阿拉丁 |